Result of General Meeting

20 July 2018
Venn Life Sciences Holdings plc
(“Venn” or the “Company” or the “Group”)

Result of General Meeting

Venn Life Sciences Holdings plc, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device clients, is pleased to announce that at the General Meeting held earlier today, all resolutions were duly passed.

As a result, the Placing announced on 4 July 2018 of 10,833,335 new ordinary shares at 6 pence per ordinary share (the “Placing Shares”), is now conditional only on Admission which is expected to take place on 24 July 2018. An application for the Placing Shares has been made to London Stock Exchange and the Irish Stock Exchange for the Placing Shares to be admitted to trading on the AIM market of the London Stock Exchange and the ESM market of the Irish Stock Exchange.

The Company also wishes to announce that an application has been made to the London Stock Exchange and the Irish Stock Exchange for 277,550 new ordinary shares (the “Vendor Shares”) of nominal value £0.001 each in the Company to be admitted to trading on the AIM market of the London Stock Exchange and the ESM market of the Irish Stock Exchange. The Vendor Shares were issued as consideration for the acquisition of the 11.03% interest in Venn Life Sciences France S.A.S as announced on 23 January 2018.

Dealings are expected to commence in both the Placing Shares and the Vendor Shares (together the “New Ordinary Shares”) at 8:00 a.m. on 24 July 2018.

The New Ordinary Shares will rank in pari passu with the existing ordinary shares in issue.

Following admission of these New Ordinary Shares, Venn’s issued share capital will consist of 71,395,148 new ordinary shares.

Enquiries:

Venn Life Sciences Holdings plc www.vennlifesciences.com
Allan Wood, Non-Executive Chairman Tel: +44 (0)7785 325 898
Tony Richardson, Chief Executive Officer Tel: +353 1 5499341

Cenkos (Nominated Adviser and Broker) Tel: +44(0)20 7397 8900
Mark Connelly/Steve Cox (Corporate Finance)

Davy (ESM Adviser and Broker) Tel: +353 1 679 6363
Fergal Meegan / Matthew de Vere White (Corporate Finance)

Hybridan LLP ( Joint Broker) Tel: +44 (0)20 3764 2341
Claire Louise Noyce

About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.